Compare AbbVie Inc (ABBV) vs Crown Castle International Corp (CCI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs Crown Castle International Corp — how do they compare? AbbVie Inc trades at $252.78 (market cap $449.91B), while Crown Castle International Corp trades at $76.93 (market cap $33.70B). The key difference: AbbVie Inc is far larger — about 13.4× Crown Castle International Corp's market cap, and Crown Castle International Corp pays the higher dividend (5.5%). Which is the better fit depends on your goals.
| ABBV | CCI | |
|---|---|---|
Market Cap | $449.91B | $33.70B |
Sector | Health | Real Estate |
52-Week High | $261.07 | $113.91 |
52-Week Low | $184.85 | $74.92 |
Enterprise Value | $513.38B | $63.53B |
Dividend Yield | 2.72% | 5.5% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $253.61, down 0.45% on the day, with strong technical momentum showing bullish moving averages and key support at $253. The company reported Q1 2026 EPS of $2.65, beating expectations, while revenue growth is supported by Skyrizi and Rinvoq offsetting Humira declines. Analysts maintain a bullish consensus with 68% buy ratings and a $266.33 price target, representing 5% upside potential.
The outlook remains positive with robust immunology portfolio performance and dividend growth, though risks include patent cliffs in the 2030s and competitive pressures. Current valuation metrics appear elevated with P/E at 124.83, requiring sustained earnings growth to justify premium multiples. The stock offers income appeal with consistent dividend payments while navigating portfolio transition.
Crown Castle (CCI) trades at $77.22, up 0.81% on the day, with a bearish technical outlook and mixed fundamentals. Recent earnings show a Q1 2026 miss but strong beats in prior quarters, while the company transitions to a pure-play U.S. tower focus after divesting its fiber business. Cash flow remains positive, but high debt levels and negative shareholder equity pose challenges. The stock is near its 52-week low, with a consensus price target of $97.33 suggesting significant upside potential.
The outlook for CCI hinges on execution of its strategic refocus and cost reductions. Opportunities include a 5.55% dividend yield and analyst optimism, but risks from elevated leverage and competitive pressures in telecom infrastructure warrant caution. Investor sentiment is divided, with technical indicators signaling near-term weakness despite long-term value arguments from bulls.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Crown Castle International Corp
Crown Castle International owns and leases roughly 40,000 cell towers in the United States. It also owns more than 85,000 route miles of fiber. It leases space on its towers to wireless service providers, which install equipment on the towers to support their wireless networks. The company's fiber is primarily leased by wireless service providers to set up small-cell network infrastructure and by enterprises for their internal connection needs. Crown Castle's towers and fiber are predominantly located in the largest U.S. cities. The company has a very concentrated customer base, with more than 70% of its revenue coming from the big three U.S. mobile carriers. Crown Castle operates as a real estate investment trust.
Read more on CCI →
